Vitreous Tamponades Market
Global Vitreous Tamponades Market: Snapshot
A highly fragmented global vitreous tamponades market is distinctive in terms of dominance of a select number of players in each region. Keen players in the market have given thrust to research and development to introduce newer products to serve the demand for case-specific products for specialty medical procedures.
The global market for vitreous tamponades is primarily driven by the increasing incidence of retinal detachment, diabetic retinopathy, macular pucker, and other retinal disorders. As per statistics of the International Diabetes Federation, around 300 million diabetes cases were reported in 2010 globally and it is estimated to reach 438 million by 2030. The rising incidence of diabetes that is related to be a major cause of diabetic retinopathy and other retinal disorders is stoking the demand for tamponades to prevent impaired vision and even blindness.
Besides this, the growing geriatric population that is more susceptible to retinal breaks is also a key factor boosting the growth of vitreous tamponades market.
A report by Transparency Market Research (TMR) estimates the global vitreous tamponades market to attract a revenue of US$89.9 mn by the end of 2025 from US$69.3 mn in 2016 at a CAGR of 3.0% for the forecast period between 2017 and 2025.
Gaseous Tamponades Gaining Traction due to Ease of Use, Low Cost
The report studies the global vitreous tamponades market on the basis of product type, end-user, and geography. Based on product type, the global vitreous tamponades market is divided into gaseous tamponades and liquid tamponades. Vis-à-vis revenue, of the two, liquid tamponades segment led the global vitreous tamponades market in 2016 accounting for 53.9% market share. The supremacy of the segment is due to the extensive use of liquid tamponades in European and Asian region for the treatment of retinal detachments, giant tears, proliferative diabetic retinopathy, and proliferative vitreoretinopathy. The segment of liquid tamponades has been further sub-segmented into silicone oil and perflurocarbon liquid. Of the two, silicone oil is anticipated to surpass in terms of growth rate during the 2017-2025 forecast period. On the other hand, the perflurocarbons liquid segment is likely to witness constant growth over the 2017-2025 forecast period as they are primarily used for the reattachment of giant retinal tears.
Gaseous tamponades, on the other hand, is expected to display the leading growth rate in the upcoming years. This is mainly because of low risk of emulsification, low cost, and ease of use. SF6, C2F8, and perfluropropane are the most common types of gaseous tamponades used in vitreoretinal surgeries worldwide. These gases offer advantages of being expansive that allows the retina and eyeball to gradually adjust to the occupying volume of the eye for better healing.
Based on end-user, the global vitreous tamponades market has been segmented into hospitals and ophthalmology clinics. Of the two, ophthalmology clinics held the leading share of the market in terms of revenue in 2016.
North America Leads Market due to High Incidence of Retinal Detachment
In terms of geography, the global vitreous tamponades market has been segmented into four major regions: North America, Asia Pacific, Europe, and Rest of the World. Powered by the U.S., North America held supremacy in terms of revenue over other key regions in the overall market in 2016. In the U.S., retinal detachment accounts as a major cause for morbidity with an incidence of 10.1 to 17.9 per 100,000 individuals.
Asia Pacific, on the other hand, is anticipated to emerge as a promising region and display increased market share over the forecast period from 2017 to 2025.
Leading players in the global vitreous tamponades market include Novartis AG, Valeant Pharmaceuticals, Dutch Ophthalmic Research Center B.V., AL. CHI. MI.A srl, Fluron GmbH, and Carl Zeiss Meditech AG.
Vitreous Tamponades Market to Gain Notable Revenues Owing to Increasing Demand from Developing Nations
The worldwide market for vitreous tamponades is fundamentally determined by the expanding frequency of retinal separation, diabetic retinopathy, macular pucker, and other retinal problems. The rising occurrence of diabetes that is identified with be a significant reason for diabetic retinopathy and other retinal problems is stirring up the interest for tamponades to forestall disabled vision and even visual deficiency. Other than this, the developing geriatric populace that is more vulnerable to retinal breaks is likewise a key factor boosting the development of vitreous tamponades market.
Based on categorization by end user, the global vitreous tamponades market is bifurcated into ophthalmology clinics, and hospitals. Among these, the market is dominated by the ophthalmology clinics segment on account of their rising popularity. Geographically, the market is dominated by North America with the United States generating the major revenue. Asia Pacific on the other side, the market is likely to witness lucrative growth opportunities in the coming years on account of the rising number of new entrants into the market.
The rising occurrence of retinal separation and other vitreoretinal messes that can be remedied with vitrectomy is decidedly affecting the vitreous tamponades market. Vitrectomy includes careful expulsion of the glassy humor to be supplanted with engineered substitutes known as glassy tamponades. In the natural eye, glassy humor is a crucial segment that goes about as nourishment and as a refractive medium. In case of injury or after maturing, the glassy humor breaks down prompting tearing or separation of the exceptionally delicate retina.
Additionally, developing old populace around the world is likewise considered as one of the key variables boosting the development of vitreous tamponades market. This is on the grounds that the matured populace has a high danger of retinal breaks that requires viable treatment.
Global vitreous tamponades market is segmented as follows:
|
by Product Type |
|
|
by End-user |
|
|
by Geography |
|
Section 1 Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights
Section 2 Assumptions and Research Methodology
2.1 Assumptions
2.2 Research Methodology
Section 3 Executive Summary
3.1 Global Vitreous Tamponades Market Snapshot, 2016
3.2 Global Vitreous Tamponades Market: Opportunity Map
Section 4 Market Overview
4.1 Overview
4.2 Global Vitreous Tamponades Market Size (US$ Mn) Forecast, 2015–2025
4.3 Global Vitreous Tamponades Market Outlook
4.5 Global Vitreous Tamponades Market: Porter's Analysis
4.6 Global Vitreous Tamponades Market: Value Chain Analysis
Section 5 Market Dynamic
5.1 Drivers
5.1.1 Rise in incidence of vitreoretinal disorders
5.1.2 Increase in geriatric population
5.1.3 Rise in health care infrastructure
5.2 Restraints
5.2.1 Complications associated with tamponades
5.2.2 Price competitiveness
5.3 Opportunities
5.3.1 Strong Research and Development Activities to Develop Novel Vitreous Tamponades
5.3.2 Expansion in Emerging Geographies by Key Players
5.4 Key Trends
5.4.1 Investigational Novel Technologies & Products
5.4.2 Use of Combinations as Intraocular Tamponades
Section 6 Global Vitreous Tamponades Market Analysis, by Product
6.1 Introduction
6.2 Global Vitreous Tamponades Market Value Share Analysis, by Product
6.3 Global Vitreous Tamponades Market Value and Volume Forecast By Product
6.3.1 Gaseous Tamponades
6.3.2 Liquid Tamponades
6.3.2.1 Silicone Oil
6.3.2.2 Perfluorocarbon Liquids (PFCL)
6.4 Global Vitreous Tamponades Market Attractiveness Analysis, by Product
Section 7 Global Vitreous Tamponades Market Analysis, by End-user
7.1 Introduction
7.2 Global Vitreous Tamponades Market Value Share Analysis, by End-user
7.3 Global Vitreous Tamponades Market Analysis, by End-user
7.3.1 Hospitals
7.3.2 Ophthalmology Clinics
7.4 Global Vitreous Tamponades Market Attractiveness Analysis, by End-user
Section 8 Global Vitreous Tamponades Market Analysis, by Region
8.1 Global Vitreous Tamponades Market Snapshot, by Country
8.2 Global Vitreous Tamponades Market Value Share Analysis, by Region
8.3 Global Vitreous Tamponades Market Forecast, by Region
8.4 Global Vitreous Tamponades Market Attractiveness Analysis, by Region
8.5 Global Vitreous Tamponades Market: Regional Trends
Section 9 North America Vitreous Tamponades Market Analysis
9.1 Key Findings
9.2 North America Vitreous Tamponades Market Overview
9.3 North America Market Value Share Analysis, by Product
9.4 North America Market Forecast, by Product
9.4.1 Gaseous Tamponades
9.4.2 Liquid Tamponades
9.4.2.1 Silicone Oil
9.4.2.2 Perfluorocarbon Liquids (PFCL)
9.5 North America Market Value Share Analysis, by End-user
9.6 North America Market Forecast, by End-user
9.6.1 Hospitals
9.6.2 Ophthalmology Clinics
9.7 Market Analysis, by Country
9.8 Market Value Share Analysis, by Country
9.9 Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
9.9.1 U.S.
9.9.2 Canada
9.1 Market Attractiveness Analysis
9.10.1 By Product
9.10.2 By End-user
9.10.3 By Country
Section 10 Europe Vitreous Tamponades Market Analysis
10.1 Key Findings
10.2 Europe Vitreous Tamponades Market Overview
10.3 Europe Market Value Share Analysis, by Product
10.4 Europe Market Forecast, by Product
10.4.1 Gaseous Tamponades
10.4.2 Liquid Tamponades
10.4.2.1 Silicone Oil
10.4.2.2 Perfluorocarbon Liquids (PFCL)
10.5 Europe Market Value Share Analysis, by End-user
10.6 Europe Market Forecast, by End-user
10.6.1 Hospitals
10.6.2 Ophthalmology Clinics
10.7 Market Analysis, by Country/Sub-region
10.8 Market Value Share Analysis, by Country/Sub-region
10.9 Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
10.9.1 Germany
10.9.2 France
10.9.3 U.K.
10.9.4 Rest of Europe
10.10 Market Attractiveness Analysis
10.10.1 By Product
10.10.2 By End-user
10.10.3 By Country/Sub-region
Section 11 Asia Pacific Vitreous Tamponades Market Analysis
11.1 Key Findings
11.2 Asia Pacific Vitreous Tamponades Market Overview
11.3 Asia Pacific Market Value Share Analysis, by Product
11.4 Asia Pacific Market Forecast, by Product
11.4.1 Gaseous Tamponades
11.4.2 Liquid Tamponades
11.4.2.1 Silicone Oil
11.4.2.2 Perfluorocarbon Liquids (PFCL)
11.5 Asia Pacific Market Value Share Analysis, by End-user
11.6 Asia Pacific Market Forecast, by End-user
11.6.1 Hospitals
11.6.2 Ophthalmology Clinics
11.7 Market Analysis, by Country/Sub-region
11.8 Market Value Share Analysis, by Country/Sub-region
11.9 Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2025
11.9.1 Japan
11.9.2 China
11.9.3 India
11.9.4 Rest of Asia Pacific
11.10 Market Attractiveness Analysis
11.10.1 By Product
11.10.2 By End-user
11.10.3 By Country/Sub-region
Section 12 Rest of the World Vitreous Tamponades Market Analysis
12.1 Key Findings
12.2 Rest of the World Vitreous Tamponades Market Overview
12.3 Rest of the World Market Value Share Analysis, by Product
12.4 Rest of the World Market Forecast, by Product
12.4.1 Gaseous Tamponades
12.4.2 Liquid Tamponades
12.4.2.1 Silicone Oil
12.4.2.2 Perfluorocarbon Liquids (PFCL)
12.5 Rest of the World Market Value Share Analysis, by End-user
12.6 Rest of the World Market Forecast, by End-user
12.6.1 Hospitals
12.6.2 Ophthalmology Clinics
12.7 Market Attractiveness Analysis
12.7.1 By Product
12.7.2 By End-user
Section 13 Company Profiles
13.1 Global Vitreous Tamponades Market: Heat Map Analysis
13.2 Competition Matrix
13.3 Company Profiles
13.3.1 Fluoron GmbH
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Product Portfolio
13.3.1.3. SWOT Analysis
13.3.1.4. Strategic Overview
13.3.2 Carl Zeiss Meditec AG
13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Financial Overview
13.3.2.3. Product Portfolio
13.3.2.4. SWOT Analysis
13.3.2.5. Strategic Overview
13.3.3 Dutch Ophthalmic Research Center (International) B.V.
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Product Portfolio
13.3.3.3. SWOT Analysis
13.3.3.4. Strategic Overview
13.3.4 AL.CHI.MI.A Srl
13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.4.2. Product Portfolio
13.3.4.3. SWOT Analysis
13.3.4.4. Strategic Overview
13.3.5 Arcadophta
13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.5.2. Product Portfolio
13.3.5.3. SWOT Analysis
13.3.5.4. Strategic Overview
13.3.6 Valeant Pharmaceuticals International, Inc.
13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.6.2. Financial Overview
13.3.6.3. Product Portfolio
13.3.6.4. SWOT Analysis
13.3.6.5. Strategic Overview
13.3.7 Novartis AG
13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.7.2. Financial Overview
13.3.7.3. Product Portfolio
13.3.7.4. SWOT Analysis
13.3.7.5. Strategic Overview
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes